[1]
FEIGENBAUM A. Description of Behçet's syndrome in the Hippocratic third book of endemic diseases. The British journal of ophthalmology. 1956 Jun:40(6):355-7
[PubMed PMID: 13355940]
[2]
de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis and rheumatism. 2009 Oct 15:61(10):1287-96. doi: 10.1002/art.24642. Epub
[PubMed PMID: 19790126]
Level 2 (mid-level) evidence
[3]
Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behçet's disease. Clinical and experimental rheumatology. 2003 Jul-Aug:21(4 Suppl 30):S44-8
[PubMed PMID: 14727460]
[4]
Mizushima Y. Behçet's disease. Current opinion in rheumatology. 1991 Feb:3(1):32-5
[PubMed PMID: 2043450]
Level 3 (low-level) evidence
[5]
Isogai E, Ohno S, Kotake S, Isogai H, Tsurumizu T, Fujii N, Yokota K, Syuto B, Yamaguchi M, Matsuda H. Chemiluminescence of neutrophils from patients with Behçet's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Archives of oral biology. 1990:35(1):43-8
[PubMed PMID: 2117912]
[6]
Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, Altas K, Yazici H. The pustular skin lesions in Behcet's syndrome are not sterile. Annals of the rheumatic diseases. 2004 Nov:63(11):1450-2
[PubMed PMID: 15479894]
[7]
Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunasti S, Usta A, Kandi B, Durusoy C, Seyhan M, Utas S, Saricaoglu H, Ozden MG, Uzun S, Tursen U, Cicek D, Donmez L, Alpsoy E. Demographic and clinical properties of juvenile-onset Behçet's disease: A controlled multicenter study. Journal of the American Academy of Dermatology. 2008 Apr:58(4):579-84
[PubMed PMID: 18045733]
Level 2 (mid-level) evidence
[8]
Treudler R, Orfanos CE, Zouboulis CC. Twenty-eight cases of juvenile-onset Adamantiades-Behçet disease in Germany. Dermatology (Basel, Switzerland). 1999:199(1):15-9
[PubMed PMID: 10449951]
Level 3 (low-level) evidence
[9]
Yazici H, Tüzün Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdoğan H, Serdaroğlu S, Ersanli M, Ulkü BY, Müftüoğlu AU. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Annals of the rheumatic diseases. 1984 Dec:43(6):783-9
[PubMed PMID: 6524980]
[10]
Koné-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, Touitou I. Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands. The Journal of pediatrics. 1999 Jul:135(1):89-93
[PubMed PMID: 10393610]
[11]
Gülbay B, Acican T, Erçen Diken Ö, Pinar Önen Z. Familial Behçet's disease of adult age: a report of 4 cases from a Behçet family. Internal medicine (Tokyo, Japan). 2012:51(12):1609-11
[PubMed PMID: 22728500]
Level 3 (low-level) evidence
[12]
Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, Tunç R, Urgancioğlu M, Dişçi R. Prevalence of Behçet's disease in Istanbul, Turkey. International journal of dermatology. 2003 Oct:42(10):803-6
[PubMed PMID: 14521694]
[13]
Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis and rheumatism. 2009 May 15:61(5):600-4. doi: 10.1002/art.24423. Epub
[PubMed PMID: 19405011]
[14]
Melikoglu M, Kural-Seyahi E, Tascilar K, Yazici H. The unique features of vasculitis in Behçet's syndrome. Clinical reviews in allergy & immunology. 2008 Oct:35(1-2):40-6. doi: 10.1007/s12016-007-8064-8. Epub
[PubMed PMID: 18172779]
[15]
Zouboulis CC, May T. Pathogenesis of Adamantiades-Behçet's disease. Advances in experimental medicine and biology. 2003:528():161-71
[PubMed PMID: 12918684]
Level 3 (low-level) evidence
[16]
Cho SB, Ahn KJ, Kim DH, Zheng Z, Cho S, Kang SW, Lee JH, Park YB, Lee KH, Bang D. Identification of HnRNP-A2/B1 as a target antigen of anti-endothelial cell IgA antibody in Behçet's disease. The Journal of investigative dermatology. 2012 Mar:132(3 Pt 1):601-8. doi: 10.1038/jid.2011.397. Epub 2011 Dec 29
[PubMed PMID: 22205302]
[17]
Jorizzo JL, Abernethy JL, White WL, Mangelsdorf HC, Zouboulis CC, Sarica R, Gaffney K, Mat C, Yazici H, al Ialaan A. Mucocutaneous criteria for the diagnosis of Behçet's disease: an analysis of clinicopathologic data from multiple international centers. Journal of the American Academy of Dermatology. 1995 Jun:32(6):968-76
[PubMed PMID: 7751467]
[18]
Yurdakul S, Yazici H, Tüzün Y, Pazarli H, Yalçin B, Altaç M, Ozyazgan Y, Tüzüner N, Müftüoğlu A. The arthritis of Behçet's disease: a prospective study. Annals of the rheumatic diseases. 1983 Oct:42(5):505-15
[PubMed PMID: 6625699]
[19]
Demirkesen C, Tüzüner N, Mat C, Senocak M, Büyükbabani N, Tüzün Y, Yazici H. Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. American journal of clinical pathology. 2001 Sep:116(3):341-6
[PubMed PMID: 11554161]
[20]
Dinç A, Karaayvaz M, Caliskaner AZ, Pay S, Erdem H, Turan M. Dermographism and atopy in patients with Behçet's disease. Journal of investigational allergology & clinical immunology. 2000 Nov-Dec:10(6):368-71
[PubMed PMID: 11206938]
[21]
Yazici H, Chamberlain MA, Tüzün Y, Yurdakul S, Müftüoglu A. A comparative study of the pathergy reaction among Turkish and British patients with Behçet's disease. Annals of the rheumatic diseases. 1984 Feb:43(1):74-5
[PubMed PMID: 6696522]
Level 2 (mid-level) evidence
[22]
Benezra D, Cohen E. Treatment and visual prognosis in Behçet's disease. The British journal of ophthalmology. 1986 Aug:70(8):589-92
[PubMed PMID: 3741823]
[23]
Karaca M, Hatemi G, Sut N, Yazici H. The papulopustular lesion/arthritis cluster of Behçet's syndrome also clusters in families. Rheumatology (Oxford, England). 2012 Jun:51(6):1053-60. doi: 10.1093/rheumatology/ker423. Epub 2012 Jan 27
[PubMed PMID: 22286924]
[24]
Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's Disease. Seminars in arthritis and rheumatism. 1998 Feb:27(4):197-217
[PubMed PMID: 9514126]
[25]
Hamuryudan V, Er T, Seyahi E, Akman C, Tüzün H, Fresko I, Yurdakul S, Numan F, Yazici H. Pulmonary artery aneurysms in Behçet syndrome. The American journal of medicine. 2004 Dec 1:117(11):867-70
[PubMed PMID: 15589493]
[26]
Al-Araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. The Lancet. Neurology. 2009 Feb:8(2):192-204. doi: 10.1016/S1474-4422(09)70015-8. Epub
[PubMed PMID: 19161910]
[27]
Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee Sarvestani S. Comparing the Effect of Phenytoin Syrup and Triamcinolone Acetonide Ointment on Aphthous Ulcers in Patients with Behcet's Syndrome. Iranian Red Crescent medical journal. 2012 Feb:14(2):75-8
[PubMed PMID: 22737559]
[28]
Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Archives of dermatology. 1999 May:135(5):529-32
[PubMed PMID: 10328192]
Level 1 (high-level) evidence
[29]
Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, Chams-Davatchi C. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Modern rheumatology. 2009:19(5):542-9. doi: 10.1007/s10165-009-0200-2. Epub 2009 Jul 14
[PubMed PMID: 19597921]
Level 1 (high-level) evidence
[30]
Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. Behçet's syndrome: a critical digest of the 2014-2015 literature. Clinical and experimental rheumatology. 2015 Nov-Dec:33(6 Suppl 94):S3-14
[PubMed PMID: 26487500]
[31]
Casajús A, Zubiaur P, Méndez M, Campodónico D, Gómez A, Navares-Gómez M, Villapalos-García G, Soria-Chacartegui P, Novalbos J, Román M, Mejía-Abril G, Ochoa D, Abad-Santos F. Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers. Advances in therapy. 2022 Apr:39(4):1743-1753. doi: 10.1007/s12325-022-02067-8. Epub 2022 Feb 22
[PubMed PMID: 35192152]
Level 3 (low-level) evidence
[32]
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Seminars in arthritis and rheumatism. 2011 Aug:41(1):61-70. doi: 10.1016/j.semarthrit.2010.09.002. Epub 2010 Dec 17
[PubMed PMID: 21168186]
[33]
Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behçet disease: review of the literature. Seminars in arthritis and rheumatism. 2004 Apr:33(5):320-35
[PubMed PMID: 15079763]
[34]
Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Archives of dermatology. 2002 Apr:138(4):467-71
[PubMed PMID: 11939808]
Level 1 (high-level) evidence
[35]
Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC, UK Dermatology Clinical Trials Network's STOP GAP Team. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. Journal of the American Academy of Dermatology. 2016 Nov:75(5):940-949. doi: 10.1016/j.jaad.2016.06.016. Epub 2016 Aug 5
[PubMed PMID: 27502313]
Level 2 (mid-level) evidence
[36]
Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Review of 21 cases. Archives of dermatology. 1989 Jan:125(1):57-64
[PubMed PMID: 2642682]
Level 3 (low-level) evidence
[37]
Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. Journal of the American Academy of Dermatology. 2005 Aug:53(2):273-83
[PubMed PMID: 16021123]
[38]
Yurdakul S, Mat C, Tüzün Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H. A double-blind trial of colchicine in Behçet's syndrome. Arthritis and rheumatism. 2001 Nov:44(11):2686-92
[PubMed PMID: 11710724]
Level 1 (high-level) evidence
[39]
Yalçindağ FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet's disease. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2012 Aug:28(4):439-43. doi: 10.1089/jop.2011.0238. Epub 2012 Mar 28
[PubMed PMID: 22455657]
[40]
Vieira M, Buffier S, Vautier M, Le Joncour A, Jamilloux Y, Gerfaud-Valentin M, Bouillet L, Lazaro E, Barete S, Misery L, Gobert D, Goulenok T, Fain O, Sacre K, Sève P, Cacoub P, Comarmond C, Saadoun D. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study. Frontiers in immunology. 2020:11():626792. doi: 10.3389/fimmu.2020.626792. Epub 2021 Feb 4
[PubMed PMID: 33613571]
Level 2 (mid-level) evidence
[41]
Atienza-Mateo B, Martín-Varillas JL, Graña J, Espinosa G, Moriano C, Pérez-Sandoval T, García-Armario MD, Castellví I, Román-Ivorra JA, Olivé A, Ybáñez A, Martinez-Ferrer A, Narváez J, Romero-Yuste S, Ojeda S, Ros I, Loricera J, Calvo-Río V, Castañeda S, Gonzalez-Gay MA, Blanco R, Spanish Collaborative Group of Refractory Behçet's Disease. Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. Clinical and experimental rheumatology. 2020 Sep-Oct:38 Suppl 127(5):69-75
[PubMed PMID: 33331268]
Level 3 (low-level) evidence
[42]
Ward EM, Woodward TA, Mazlumzadeh M, Calamia KT. Gastrointestinal disease in Behçet's disease. Advances in experimental medicine and biology. 2003:528():459-64
[PubMed PMID: 12918744]
Level 3 (low-level) evidence
[43]
Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K, Nagahori M, Arai K, Uchino M, Koganei K, Kobayashi T, Takeno M, Ueno F, Matsumoto T, Mizuki N, Suzuki Y, Hisamatsu T. Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. Journal of gastroenterology. 2020 Jul:55(7):679-700. doi: 10.1007/s00535-020-01690-y. Epub 2020 May 7
[PubMed PMID: 32377946]
Level 1 (high-level) evidence
[44]
Mohammadi M, Shahram F, Shams H, Akhlaghi M, Ashofteh F, Davatchi F. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study. International journal of rheumatic diseases. 2017 Sep:20(9):1269-1276. doi: 10.1111/1756-185X.13095. Epub 2017 May 19
[PubMed PMID: 28524639]
Level 3 (low-level) evidence
[45]
Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. The British journal of ophthalmology. 2010 Mar:94(3):284-8. doi: 10.1136/bjo.2009.158840. Epub 2009 Aug 18
[PubMed PMID: 19692382]
[46]
Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clinical rheumatology. 2017 Jan:36(1):183-189. doi: 10.1007/s10067-016-3480-x. Epub 2016 Nov 16
[PubMed PMID: 27853889]
Level 2 (mid-level) evidence
[47]
Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji A. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. Journal of neurology. 2014 Sep:261(9):1662-76. doi: 10.1007/s00415-013-7209-3. Epub 2013 Dec 24
[PubMed PMID: 24366648]
Level 3 (low-level) evidence
[48]
Calleja Algarra A, Aragón Miguel R, Andrés Lencina JJ, Pinilla Martín B, Vico Alonso C, Rodríguez Peralto JL, Ortiz Romero PL, Rivera Díaz R. Behçet's-like disease during secukinumab treatment: new paradoxical reaction? Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2021 Jan:19(1):116-118. doi: 10.1111/ddg.14196. Epub 2020 Aug 10
[PubMed PMID: 32776677]